Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 March 1999Website:
http://www.lisata.comNext earnings report:
N/ALast dividends:
28 October 2013Next dividends:
N/APrice
after hours | Fri, 01 Nov 2024 21:02:31 GMTDividend
Analysts recommendations
Institutional Ownership
LSTA Latest News
Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and the University of Cincinnati aimed at investigating an endometriosis treatment. Dr Buck highlighted Certepetide, Lisata's novel cyclic peptide therapeutic that targets integrins and neuropilin receptors, which are notably elevated in both solid tumors and endometriosis.
Lisata Therapeutics, Inc. (LSTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Strategic partnership explores therapeutic effect of Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab Strategic partnership explores therapeutic effect of Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has started treatment of the first patient in the second-line cholangiocarcinoma (CCA) cohort of its BOLSTER trial. CCA, also known as bile duct cancer, has a five-year survival rate less than 5%, highlighting the urgent need for new and effective treatments.
BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will present at the following events in September:
BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma.
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo told shareholders that the company is coming off a quarter with “strong momentum” to advance clinical studies on its investigational product, certepetide. The biotech firm is looking forward to crucial data readouts from ongoing trials, particularly the Phase 2b ASCEND trial, which could lead to transformative outcomes and potential regulatory approvals.
Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck joined Proactive to discuss the company's new research collaboration with Haystack Oncology which will evaluate the efficacy of its drug candidate certepetide as a therapy for pancreatic cancer. She detailed the collaboration, which will leverage Haystack's minimal residual disease (MRD) technology to detect circulating tumor DNA in blood, which can indicate cancer recurrence or progression.
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a research collaboration with Haystack Oncology using Haystack's MRD technology to evaluate the efficacy of its investigational pancreatic cancer therapy certepetide. Per the research agreement, Lisata will deploy the Haystack MRD technology for the detection of circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.
Lisata (LSTA) is progressing well with developing its lead investigational pipeline candidate, certepetide, which is being studied for various cancer indications.
- 1(current)
- 2
What type of business is Lisata Therapeutics?
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
What sector is Lisata Therapeutics in?
Lisata Therapeutics is in the Healthcare sector
What industry is Lisata Therapeutics in?
Lisata Therapeutics is in the Biotechnology industry
What country is Lisata Therapeutics from?
Lisata Therapeutics is headquartered in United States
When did Lisata Therapeutics go public?
Lisata Therapeutics initial public offering (IPO) was on 01 March 1999
What is Lisata Therapeutics website?
https://www.lisata.com
Is Lisata Therapeutics in the S&P 500?
No, Lisata Therapeutics is not included in the S&P 500 index
Is Lisata Therapeutics in the NASDAQ 100?
No, Lisata Therapeutics is not included in the NASDAQ 100 index
Is Lisata Therapeutics in the Dow Jones?
No, Lisata Therapeutics is not included in the Dow Jones index
When was Lisata Therapeutics the previous earnings report?
No data
When does Lisata Therapeutics earnings report?
Next earnings report date is not announced yet